Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications, Infectious | 8 | 2021 | 2127 | 0.800 |
Why?
|
| Post-Exposure Prophylaxis | 3 | 2015 | 104 | 0.690 |
Why?
|
| Infectious Disease Transmission, Vertical | 4 | 2012 | 1349 | 0.570 |
Why?
|
| Syphilis | 2 | 2011 | 240 | 0.400 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2011 | 37 | 0.400 |
Why?
|
| Treponema pallidum | 1 | 2011 | 47 | 0.390 |
Why?
|
| HIV Seropositivity | 3 | 2023 | 955 | 0.340 |
Why?
|
| HIV Infections | 12 | 2023 | 17159 | 0.320 |
Why?
|
| Ambulatory Care | 2 | 2015 | 2783 | 0.290 |
Why?
|
| Emergency Medical Services | 2 | 2015 | 1927 | 0.270 |
Why?
|
| HIV Protease Inhibitors | 2 | 2016 | 432 | 0.250 |
Why?
|
| Viral Load | 5 | 2023 | 3323 | 0.220 |
Why?
|
| Anti-HIV Agents | 3 | 2015 | 4492 | 0.200 |
Why?
|
| Mass Screening | 2 | 2020 | 5422 | 0.190 |
Why?
|
| Immunoglobulin G | 2 | 2011 | 4546 | 0.170 |
Why?
|
| Papillomaviridae | 1 | 2005 | 1117 | 0.170 |
Why?
|
| Dendritic Cells | 2 | 2020 | 2730 | 0.150 |
Why?
|
| Coccidioides | 1 | 2017 | 18 | 0.150 |
Why?
|
| Coccidioidomycosis | 1 | 2017 | 37 | 0.140 |
Why?
|
| Encephalitis, Tick-Borne | 1 | 2017 | 37 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2012 | 2569 | 0.140 |
Why?
|
| Anti-Retroviral Agents | 1 | 2005 | 1780 | 0.130 |
Why?
|
| Lymphoma, AIDS-Related | 2 | 1995 | 79 | 0.130 |
Why?
|
| Medical Tourism | 1 | 2016 | 52 | 0.130 |
Why?
|
| Pregnancy Outcome | 1 | 2006 | 2906 | 0.120 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 749 | 0.120 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2016 | 165 | 0.110 |
Why?
|
| RNA, Viral | 3 | 2023 | 2837 | 0.110 |
Why?
|
| Papillomavirus Infections | 1 | 2005 | 1600 | 0.110 |
Why?
|
| Rape | 1 | 2014 | 130 | 0.110 |
Why?
|
| Virus Replication | 2 | 2020 | 2431 | 0.110 |
Why?
|
| Receptors, IgE | 1 | 1995 | 377 | 0.110 |
Why?
|
| Immunoglobulin Class Switching | 1 | 1995 | 289 | 0.110 |
Why?
|
| Osteomyelitis | 1 | 2017 | 407 | 0.110 |
Why?
|
| Pregnancy | 8 | 2021 | 29725 | 0.100 |
Why?
|
| Agglutination Tests | 1 | 2011 | 41 | 0.100 |
Why?
|
| HIV | 2 | 2016 | 1579 | 0.100 |
Why?
|
| Hepatitis C Antibodies | 2 | 2008 | 145 | 0.090 |
Why?
|
| Actinomycetales | 1 | 2011 | 31 | 0.090 |
Why?
|
| Actinomycetales Infections | 1 | 2011 | 30 | 0.090 |
Why?
|
| Preconception Care | 1 | 2012 | 139 | 0.090 |
Why?
|
| Pleurisy | 1 | 2011 | 54 | 0.090 |
Why?
|
| Cesarean Section | 2 | 2012 | 1386 | 0.090 |
Why?
|
| Eye Infections | 1 | 2010 | 62 | 0.090 |
Why?
|
| Postnatal Care | 1 | 2012 | 260 | 0.090 |
Why?
|
| Surgery, Plastic | 1 | 2016 | 640 | 0.080 |
Why?
|
| Zidovudine | 2 | 2005 | 624 | 0.080 |
Why?
|
| Labor, Obstetric | 1 | 2012 | 321 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1705 | 0.080 |
Why?
|
| Low Back Pain | 1 | 2017 | 979 | 0.080 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2014 | 628 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2016 | 6499 | 0.080 |
Why?
|
| B-Lymphocytes | 3 | 2020 | 4739 | 0.080 |
Why?
|
| Hepatitis C | 2 | 2008 | 1578 | 0.070 |
Why?
|
| HIV-1 | 1 | 2023 | 6850 | 0.070 |
Why?
|
| Uterine Cervicitis | 1 | 2005 | 31 | 0.070 |
Why?
|
| Lymphogranuloma Venereum | 1 | 2005 | 14 | 0.070 |
Why?
|
| Anus Diseases | 1 | 2005 | 55 | 0.060 |
Why?
|
| Antibodies, Bacterial | 1 | 2011 | 1470 | 0.060 |
Why?
|
| Adult | 17 | 2021 | 219847 | 0.060 |
Why?
|
| Herpes Genitalis | 1 | 2005 | 142 | 0.060 |
Why?
|
| Herpesvirus 2, Human | 1 | 2005 | 190 | 0.060 |
Why?
|
| Lamivudine | 1 | 2005 | 363 | 0.060 |
Why?
|
| Bacteremia | 1 | 2011 | 979 | 0.060 |
Why?
|
| Breast Feeding | 1 | 2012 | 1356 | 0.060 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2004 | 138 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3086 | 0.050 |
Why?
|
| Medication Adherence | 1 | 2014 | 2163 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3206 | 0.050 |
Why?
|
| Proviruses | 1 | 2023 | 313 | 0.050 |
Why?
|
| Compassionate Use Trials | 1 | 2021 | 50 | 0.050 |
Why?
|
| Young Adult | 5 | 2016 | 58673 | 0.050 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2005 | 387 | 0.050 |
Why?
|
| Female | 16 | 2023 | 391011 | 0.050 |
Why?
|
| Humans | 24 | 2023 | 760261 | 0.050 |
Why?
|
| Thiazolidinediones | 1 | 2004 | 465 | 0.050 |
Why?
|
| Viremia | 1 | 2023 | 708 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2014 | 3159 | 0.040 |
Why?
|
| Culicidae | 1 | 2020 | 108 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2004 | 854 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 283 | 0.040 |
Why?
|
| Asymptomatic Infections | 1 | 2020 | 131 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2023 | 4355 | 0.040 |
Why?
|
| Cohort Studies | 4 | 2015 | 41317 | 0.040 |
Why?
|
| Alanine | 1 | 2021 | 607 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2012 | 26168 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2005 | 1128 | 0.040 |
Why?
|
| Sex Factors | 1 | 2011 | 10530 | 0.040 |
Why?
|
| Antibodies, Fungal | 1 | 2017 | 34 | 0.040 |
Why?
|
| Disease Vectors | 1 | 2017 | 61 | 0.040 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 117 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 1655 | 0.030 |
Why?
|
| Pregnant Women | 1 | 2021 | 563 | 0.030 |
Why?
|
| Lung Diseases, Fungal | 1 | 2017 | 125 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 14656 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2020 | 821 | 0.030 |
Why?
|
| Age Factors | 1 | 2011 | 18415 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 7809 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2020 | 18968 | 0.030 |
Why?
|
| Boston | 2 | 2020 | 9282 | 0.030 |
Why?
|
| HIV Seronegativity | 1 | 1995 | 208 | 0.030 |
Why?
|
| Premature Birth | 1 | 2006 | 1771 | 0.030 |
Why?
|
| Risk | 1 | 2006 | 9629 | 0.030 |
Why?
|
| Oxazines | 1 | 2016 | 341 | 0.030 |
Why?
|
| Postoperative Complications | 1 | 2016 | 15680 | 0.030 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2016 | 582 | 0.030 |
Why?
|
| Solubility | 1 | 1995 | 1088 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2005 | 2018 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2016 | 275 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2020 | 1828 | 0.030 |
Why?
|
| North America | 1 | 2017 | 1282 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2016 | 732 | 0.030 |
Why?
|
| Cough | 1 | 2017 | 595 | 0.030 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2016 | 618 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2004 | 3149 | 0.020 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 2204 | 0.020 |
Why?
|
| Monocytes | 1 | 2020 | 2574 | 0.020 |
Why?
|
| Pyridones | 1 | 2016 | 788 | 0.020 |
Why?
|
| Cardiolipins | 1 | 2010 | 81 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 25928 | 0.020 |
Why?
|
| Drainage | 1 | 2016 | 1161 | 0.020 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 1614 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2011 | 285 | 0.020 |
Why?
|
| Middle Aged | 6 | 2014 | 220175 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 2010 | 406 | 0.020 |
Why?
|
| Immunoglobulin E | 1 | 1995 | 1493 | 0.020 |
Why?
|
| Male | 8 | 2023 | 359413 | 0.020 |
Why?
|
| Blood | 1 | 2011 | 586 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2020 | 3046 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2017 | 1867 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 1 | 2010 | 544 | 0.020 |
Why?
|
| Gestational Age | 1 | 2016 | 3564 | 0.020 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2011 | 1006 | 0.020 |
Why?
|
| Health Services Research | 1 | 2014 | 1811 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 4554 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2010 | 1600 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2020 | 7593 | 0.020 |
Why?
|
| DNA, Bacterial | 1 | 2011 | 1455 | 0.020 |
Why?
|
| Microscopy | 1 | 2011 | 881 | 0.020 |
Why?
|
| Weight Loss | 1 | 2017 | 2683 | 0.020 |
Why?
|
| Pneumonia | 1 | 2017 | 2138 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2017 | 4494 | 0.020 |
Why?
|
| Piperazines | 1 | 2016 | 2520 | 0.020 |
Why?
|
| Time Factors | 3 | 2016 | 40133 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 7400 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2004 | 12100 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2011 | 1295 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 9388 | 0.010 |
Why?
|
| Disease Progression | 2 | 2005 | 13505 | 0.010 |
Why?
|
| Cell Line | 1 | 2017 | 15626 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1994 | 5498 | 0.010 |
Why?
|
| Developing Countries | 1 | 2016 | 2880 | 0.010 |
Why?
|
| Prevalence | 1 | 2020 | 15687 | 0.010 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2004 | 393 | 0.010 |
Why?
|
| Retrospective Studies | 3 | 2016 | 80301 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 12968 | 0.010 |
Why?
|
| Hepacivirus | 1 | 2008 | 1333 | 0.010 |
Why?
|
| Hyperinsulinism | 1 | 2004 | 398 | 0.010 |
Why?
|
| Cholesterol | 1 | 2010 | 2925 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 20484 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8621 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2011 | 4717 | 0.010 |
Why?
|
| Infant | 1 | 2021 | 36030 | 0.010 |
Why?
|
| Adiponectin | 1 | 2004 | 1115 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 17628 | 0.010 |
Why?
|
| Animals | 2 | 2020 | 167940 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2005 | 1894 | 0.010 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 1994 | 317 | 0.010 |
Why?
|
| Lipids | 1 | 2004 | 3336 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 58947 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 12532 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2004 | 3960 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2004 | 12412 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1994 | 1529 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2014 | 54263 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 6030 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1994 | 1075 | 0.000 |
Why?
|
| Substance-Related Disorders | 1 | 2005 | 4370 | 0.000 |
Why?
|
| Adolescent | 1 | 2014 | 87747 | 0.000 |
Why?
|
| Interleukin-6 | 1 | 1994 | 3207 | 0.000 |
Why?
|
| Treatment Outcome | 1 | 2010 | 64947 | 0.000 |
Why?
|
| Risk Factors | 1 | 2008 | 74269 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1994 | 10183 | 0.000 |
Why?
|
Concepts
(183)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(59)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_